We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+28.34%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$15.2B
AUM Growth
+$1.87B
Cap. Flow
+$90.5M
Cap. Flow %
0.6%
Top 10 Hldgs %
84.66%
Holding
125
New
12
Increased
14
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$50.5M
2
AMRN
Amarin Corp
AMRN
+$43.1M
3
INSM icon
Insmed
INSM
+$26M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.8M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$22.4M
2
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$20.8M
3
HALO icon
Halozyme
HALO
+$14.6M
4
EXEL icon
Exelixis
EXEL
+$11M
5
XNCR icon
Xencor
XNCR
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.42%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRNB
26
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$52.2M 0.34%
+1,787,807
New +$50.5M
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
$48.9M 0.32%
1,600,000
– –
ECYT
28
DELISTED
Endocyte, Inc. Common Stock
ECYT
$45.3M 0.3%
2,548,069
+270,270
+12% +$4.64M
ACGN
29
DELISTED
Aceragen Inc
ACGN
$43.1M 0.28%
284,631
+120
+0% +$17.1K
INSM icon
30
Insmed
INSM
$27.5B
$37.4M 0.25%
1,851,982
+1,151,982
+165% +$26M
NGNE icon
31
Neurogene
NGNE
$773M
$32M 0.21%
546,708
– –
ABEO icon
32
Abeona Therapeutics
ABEO
$348M
$28M 0.18%
87,375
– –
SLDB icon
33
Solid Biosciences
SLDB
$997M
$27.7M 0.18%
39,192
– –
LKFT
34
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$26.7M 0.18%
237,191
-22,703
-9% -$2.4M
XNCR icon
35
Xencor
XNCR
$2.07B
$23.5M 0.15%
602,495
-269,577
-31% -$11M
MYOK
36
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$23.3M 0.15%
357,215
-75,906
-18% -$4.46M
MRUS
37
DELISTED
Merus
MRUS
$22.9M 0.15%
1,160,014
– –
QURE icon
38
uniQure
QURE
$3.36B
$22M 0.15%
605,000
– –
SGMO
39
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$21.8M 0.14%
1,283,923
– –
CMTA
40
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$21.6M 0.14%
1,933,624
+741,029
+62% +$7.8M
ZYME icon
41
Zymeworks
ZYME
$2.05B
$20.6M 0.14%
1,311,085
– –
AIMT
42
DELISTED
Aimmune Therapeutics
AIMT
$18.4M 0.12%
673,908
– –
BLCM
43
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$16.5M 0.11%
267,782
-141,563
-35% -$9.58M
BOLD
44
DELISTED
Audentes Therapeutics, Inc
BOLD
$15.6M 0.1%
393,222
– –
CFRX
45
DELISTED
ContraFect Corporation
CFRX
$14.8M 0.1%
8,941
– –
SYRE icon
46
Spyre Therapeutics
SYRE
$9.39B
$13.3M 0.09%
55,515
– –
ANAB icon
47
AnaptysBio
ANAB
$1.71B
$11.3M 0.07%
113,086
+40,000
+55% +$3.32M
CPRX
48
DELISTED
Catalyst Pharmaceutical
CPRX
$11M 0.07%
2,900,000
-721,962
-20% -$2.26M
PHXM
49
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$9.31M 0.06%
108,597
-200,000
-65% -$20.8M
NVAX icon
50
Novavax
NVAX
$1.47B
$8.87M 0.06%
+235,916
New +$6.64M
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2018 Portfolio in Review

As of Q3 2018, Julian Baker held 125 positions worth $15.2B, up 14% from $13.3B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q3 2018 filing shows 12 new, 14 increased, 21 reduced and 27 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M. The largest sale was bluebird bio, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,787,807 shares worth $52.2M.
  • Julian Baker added most to Amarin Corp in Q3 2018, an estimated $43.1M increase.
  • Julian Baker's biggest Q3 2018 reduction was bluebird bio, cutting an estimated $22.4M.
  • Julian Baker fully exited Exelixis in Q3 2018, selling an estimated $11M.
  • Julian Baker's ten largest holdings make up 85% of its $15.2B portfolio in Q3 2018.
  • Julian Baker opened 12 new positions and closed 27 in Q3 2018.
  • Julian Baker's portfolio value rose 14% quarter-over-quarter to $15.2B.

Based on Baker Bros. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.